EUVIMEDEUVIMED entdecken
Open Access

Low‑dose venetoclax combined with azacitidine in older and frail patients with newly diagnosed acute myeloid leukaemia

Chunmeng Rong, Fang Yang, Yalu Chen, Ming Wang, Cheng Ai, Yuqing Luo, Panpan Gao, Yiqin Weng, Xiaguang Huang, Meier Gu, Weiping Huang, Yongming Xia

Oncology Letters · 26.03.2024 · 27 (5)

DOI: 10.3892/ol.2024.14362 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Letters, online erschienen am 26.03.2024. Verfasst von Chunmeng Rong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematopathology, Yuyao People's Hospital, Yuyao, Zhejiang 315400, P.R. China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the present study, the aim was to evaluate the clinical efficacy and safety of low-dose venetoclax combined with azacitidine for the treatment of older and frail patients with newly diagnosed acute myeloid leukaemia (AML). Data of 26 older patients with newly diagnosed AML admitted to Yuyao People's Hospital (Yuyao, China) between January 2021 and May 2023 were retrospectively analysed. The treatment regimens were as follows: Subcutaneous injection of 100 mg azacitidine on days 1-5 and 100 mg oral venetoclax on days 3-16 or 200 mg oral venetoclax on days 3-30. The median age of the 26 patients was 73 years. After the first course of treatment, the complete remission (CR) and CR with incomplete haematological recovery rate was 84.6%, and the objective response rate was 96.2%. The most common adverse events noted during treatment were haematological adverse events including grade 3/4 granulocytosis (57.7%), febrile neutropenia (30.8%), pulmonary infection (32.0%), thrombocytopenia (42.3%) and anaemia (42.3%). A total of 13 (50.0%) patients did not require platelet (PLT) infusion during treatment. The main non-haematological adverse reactions included gastrointestinal reactions such as nausea, vomiting and diarrhoea. Patients were followed up until December 2023, with a median follow-up time of 9.5 months (range, 1.9-26.0 months). Of the 26 patients, nine (34.6%) patients experienced relapse, with a mean recurrence time of 5.9 months. In conclusion, preliminary results indicated that low-dose venetoclax combined with azacitidine is effective and safe for the treatment of older and frail patients with newly diagnosed AML, providing a new treatment option for these patients.

Schlagwörter

Stichwörter der Autor:innen

acute myeloid leukaemiaazacitidinenewly diagnosedolder patientsvenetoclax

Autor:innen und Institutionen

  • Department of Hematopathology, Yuyao People's Hospital, Yuyao, Zhejiang 315400, P.R. China.
  • Clinical Laboratory Department, Yuyao People's Hospital, Yuyao, Zhejiang 315400, P.R. China.

Zitieren

APA

Rong, C., Yang, F., Chen, Y., Wang, M., Ai, C., Luo, Y., Gao, P., Weng, Y., Huang, X., Gu, M., Huang, W., & Xia, Y. (2024). Low‑dose venetoclax combined with azacitidine in older and frail patients with newly diagnosed acute myeloid leukaemia. Oncology Letters, 27(5). https://doi.org/10.3892/ol.2024.14362

Vancouver

Rong C, Yang F, Chen Y, Wang M, Ai C, Luo Y, et al. Low‑dose venetoclax combined with azacitidine in older and frail patients with newly diagnosed acute myeloid leukaemia. Oncology Letters. 2024;27(5). doi:10.3892/ol.2024.14362

BibTeX
@article{Rong2024,
  author = {Rong, Chunmeng and Yang, Fang and Chen, Yalu and Wang, Ming and Ai, Cheng and Luo, Yuqing and Gao, Panpan and Weng, Yiqin and Huang, Xiaguang and Gu, Meier and Huang, Weiping and Xia, Yongming},
  title = {Low‑dose venetoclax combined with azacitidine in older and frail patients with newly diagnosed acute myeloid leukaemia},
  journal = {Oncology Letters},
  year = {2024},
  volume = {27},
  number = {5},
  doi = {10.3892/ol.2024.14362}
}
Kostenlos starten →